Condition: Plaque Psoriasis · Sponsor: Aurigene Discovery Technologies Limited
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Johnson Dermatology | Fort Smith, Arkansas, United States | — |
| Northwest AR Clinical Trials Center | Rogers, Arkansas, United States | — |
| First OC Dermatology | Fountain Valley, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| University Clinical Trials, Inc. | San Diego, California, United States | — |
| Clinical Science Institute | Santa Monica, California, United States | — |
| Unison Clinical Trials | Sherman Oaks, California, United States | — |
| Moore Clinical Research, Inc. | Brandon, Florida, United States | — |
| Skin Research Institute | Coral Gables, Florida, United States | — |
| Accel Research Sites - Deland CRU | DeLand, Florida, United States | — |
| FXM Clinical Research Fort Lauderdale | Fort Lauderdale, Florida, United States | — |
| Direct Helpers Research Center | Hialeah, Florida, United States | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04855721